Open AccessCardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib
Author(s) -
Lucia Petríková,
Katarína Slezáková,
Zuzana Sninská,
Ľubica Harvanová,
M Martisova,
Antónia Hatalova,
Martin Mistrík,
Angelika Bátorová,
Beata Mladosievičová
Publication year - 2021
Publication title -
bratislavské lekárske listy/bratislava medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 32
eISSN - 1336-0345
pISSN - 0006-9248
DOI - 10.4149/bll_2021_085
Subject(s) - nilotinib , medicine , dyslipidemia , imatinib , myeloid leukemia , tyrosine kinase inhibitor , lipid profile , myocardial infarction , adverse effect , cardiotoxicity , pharmacology , gastroenterology , cholesterol , disease , cancer , toxicity
The aim of this study was to assess cardiotoxicity and potential adverse effects related to lipid metabolism during treatment with tyrosine kinase inhibitors (TKIs) imatinib and nilotinib in patients with chronic myeloid leukemia (CML).